
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. is poised for significant growth, driven by the anticipated clinical data readouts of its proprietary mRNA development programs in 2025, which could lead to substantial appreciation in its stock value if results are favorable. The company's revenue projection of over $500 million five years post-launch highlights its potential in the market, supported by the recent European Commission marketing authorization for its COVID-19 vaccine, Kostaive, which adds to its growing portfolio. Furthermore, the collaboration with CSL Seqirus to commercialize Kostaive reduces execution risk, enhancing the company's prospects as it expands its manufacturing capabilities in Japan.
Bears say
The financial outlook for Arcturus Therapeutics Holdings Inc. is negative due to significant revisions in revenue estimates for its COVID-19 product, Kostaive, which has been downgraded from $156.4 million to $11.8 million for the 2026 fiscal year, following lower-than-expected vaccination projections. Additionally, the company reported a net loss of $30 million for the fourth quarter of 2024, indicating ongoing operational challenges, despite holding approximately $294 million in cash and equivalents. The analysis is further hindered by several high-risk factors, including potential safety concerns related to its mRNA drugs, the possibility of unsuccessful clinical trials, and risks associated with regulatory approvals, which collectively weigh heavily on investor confidence.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares